This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related letter  • Similar articles in this journal  Topic Collections  • Neurocutaneous Diseases  • Alert me on articles by topic

Sabrina Buoni, MD; Raffaella Zannolli, MD; Livio Sorrentino, MD; Alberto Fois, MD

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In reply

We read with interest the letter from Gazulla et al in which they treated a 34-year-old man with AT with a combination of pregabalin (225 mg/d) and tiagabine (7.5 mg/d). The authors reported that pregabalin treatment improved the patient's gait (ie, he could walk more than 10 m without support) and that the addition of tiagabine increased the distance of unsupported walking to more than 20 m and facilitated execution of half turns. The improvements were sustained for an unspecified period after which the beneficial effects of the drugs disappeared and the drugs were withdrawn. Based on their observations, Gazulla et al proposed using pregabalin and tiagabine together rather than betamethasone to treat children with AT in whom we first raised several concerns about adverse effects.¹

Previously, Gazulla et al reported some positive results treating ataxia . . . [Full Text of this Article]

AUTHOR INFORMATION

RELATED LETTER

New Therapies for Ataxia-Telangiectasia
José Gazulla, Isabel Benavente, and Manuel Sarasa
Arch Neurol. 2007;64(4):607-608.
EXTRACT | FULL TEXT